Trevena (NASDAQ:TRVN) Stock Passes Below 200-Day Moving Average – Here’s Why

Trevena, Inc. (NASDAQ:TRVN) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $6.46 and traded as low as $1.82. Trevena shares last traded at $1.99, with a volume of 4,056 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Trevena in a research report on Saturday. They issued a “sell” rating for the company.

Trevena Stock Performance

The company has a market cap of $36.50 million, a P/E ratio of -0.74 and a beta of 1.02. The business has a fifty day simple moving average of $3.77 and a 200 day simple moving average of $6.46.

Trevena (NASDAQ:TRVN) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($9.25) by $9.02. The business had revenue of $0.33 million during the quarter. Equities research analysts expect that Trevena, Inc. will post -32.25 EPS for the current year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.